Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Gabather: High potential in specific modulation - VH Corp

Gabather

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
• Novel therapeutics addressing the GABAA receptor system in the CNS
• An exploratory phase II study in schizophrenia is ongoing
• We initiate coverage with a fair value of SEK 0.092 per share

Gabather is a drug developer in precision medicine targeting mental health disorders. By developing a specific GABAA receptor modulator in the central nervous system (CNS), the company engages in a new approach to a therapeutic area with great unmet medical need.

The lead drug candidate, GT-002, is a potential first-in-class drug with solid clinical data from phase I studies. GT-002 is currently undergoing an exploratory phase II study in schizophrenia, the TOTEMS study, financed by Innovation Fund Denmark.

Gabather’s current market cap amounts to approximately MSEK 11. Despite acknowledging the development risk and recognising a substantial financial risk, we see a significant potential in the valuation given the market opportunity.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.